Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

By Alana Hippensteele, MA

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 22nd 2018

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.

February 22nd 2018

Diminished Employment Participation After Breast Cancer Linked to Race and Insurance Status

African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg

CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.

What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies

February 21st 2018

What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies

Research analyzes the cost of processing healthcare bills; supermarket operator Albertsons will buy drugstore chain Rite Aid; a review of phase 1 clinical trials finds just 1 in 10 children with cancer see improvements.

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.

February 21st 2018

Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.

February 21st 2018

Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry

Samantha DiGrande

Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.

February 21st 2018

The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"

Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.

Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care

February 20th 2018

Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care

Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh, notes important value coordinates of breast cancer care.

February 20th 2018

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm

This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.

Cancer Survivors Manage Fatigue With Placebo Pills

February 19th 2018

Cancer Survivors Manage Fatigue With Placebo Pills

Cancer survivors may be able to manage the extreme fatigue they experience after treatment by knowingly taking a placebo pill, according to researchers at University of Alabama at Birmingham and Harvard Medical School.

USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women

February 18th 2018

USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women

Jaime Rosenberg

The US Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome because evidence shows that screening does not reduce ovarian cancer mortality.

February 17th 2018

Variation in Markups on Outpatient Oncology Services in the United States

Angela Park Tim Xu, MD, MPP Michael Poku, MD, MBA James Taylor, MBBChir, MPH, MRCS(Eng) Martin A. Makary, MD, MPH

Charges for oncology services vary widely across hospitals and impose financial burdens. Further legislation is needed to address disparities in access to high-quality cancer care.

Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000

February 17th 2018

Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000

Merkel cell carcinoma (MCC) is a rare disease, but it's getting less rare. Study results presented at the American Academy of Dermatology 2018 Annual Meeting found that cases of MCC increased 95% between 2000 and 2013

February 17th 2018

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm

February 16th 2018

Development of a Tailored Survey to Evaluate a Patient-Centered Initiative

Marcy Winget, PhD Farnoosh Haji-Sheikhi, MS Steve M. Asch, MD, MPH

We developed short patient experience surveys that were sensitive to our broad quality initiative, were meaningful and acceptable to patients, and had good response rates.

AJMC® in the Press, February 16, 2018

February 16th 2018

AJMC® in the Press, February 16, 2018

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Roche Acquires Flatiron Health for $1.9 Billion

February 16th 2018

Roche Acquires Flatiron Health for $1.9 Billion

Flatiron Health expects to maintain its current business model in the transaction.

Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology

February 16th 2018

Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology

Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.

February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS

The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.

Family History Associated With Breast Cancer Risk for Women 65 and Older

February 15th 2018

Family History Associated With Breast Cancer Risk for Women 65 and Older

Jaime Rosenberg

First-degree family history was associated with an increased risk of breast cancer among women aged 65 and older, and risk associated with family history was not significantly modified by breast density, according to a study in JAMA Oncology.

FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer

February 15th 2018

FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer

Laura Joszt, MA

FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.

February 15th 2018

ASCO and NCCN Release Guidelines on Managing Immunotherapy-Related Toxicities

The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have developed new guidelines on managing immune checkpoint inhibitor-related toxicities.

February 14th 2018

Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer

Jaime Rosenberg

There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.

ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines

February 13th 2018

ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines

Samantha DiGrande

Last week, the American Society of Clinical Oncology (ASCO) published its review of the leading oncology pathway vendors in the United States in the Journal of Oncology Practice. The report found that overall, the prominent commercial pathway programs in the United States are aligned with ASCO’s evaluation criteria.

Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care

February 13th 2018

Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care

Jaime Rosenberg

Medicaid expansion in Kentucky led to an increase of screening mammograms, screening coverage, and breast-conserving surgery for women aged 20 to 64 with breast cancer, according to a study published in the Journal of the American College of Surgeons. However, the study also showed that time from diagnosis to operation increased post expansion and time from operation to chemotherapy remained unchanged.

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

February 12th 2018

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.

Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer

February 11th 2018

Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer

In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.

Podcast: This Week in Managed Care—Cancer Survival Rates and Other Health News

February 10th 2018

Podcast: This Week in Managed Care—Cancer Survival Rates and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 10th 2018

Docetaxel Plus Hormone Therapy Improved QoL, Cost Effectiveness in Prostate Cancer

Jaime Rosenberg

The addition of docetaxel to first-line long-term hormone therapy in patients with prostate cancer is associated with improved quality of life (QoL) benefits and cost effectiveness, according to study results presented at the 2018 Genitourinary Cancers Symposium.

...

58 59 60 61 62 63 64 65 66

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions